C:\Program Files\Common Files\System\Mapi\1033\NT





chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-13 8-13 14-22 15-24 16-17 18-19 20-21 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-13 8-13 14-22 15-24 22-23
exact bonds :
16-17 18-19 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:CH2,NH,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 38:Atom 39:CLASS
Generic attributes :
38:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :

Node 38: Limited
C,C4
N,N1
O,O0
S,S0

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10671747.str









chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-13 8-13 14-22 15-24 16-17 18-19 20-21 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-13 8-13 14-22 15-24 22-23
exact bonds :
16-17 18-19 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:CH2,NH,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 38:Atom 39:CLASS
Generic attributes :
38:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 38: Limited
C,C4
N,N1
O,O0
S,S0

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1 SCR 1840
L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam
SAMPLE SEARCH INITIATED 19:06:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3845 TO ITERATE

26.0% PROCESSED 1000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 73182 TO 80618
PROJECTED ANSWERS: 27 TO 433

```
L5              3 SEA SSS SAM L3 AND L1 NOT L2

=> => s l4 sss ful
FULL SEARCH INITIATED 19:06:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  76755 TO ITERATE

100.0% PROCESSED   76755 ITERATIONS                          95 ANSWERS
SEARCH TIME: 00.00.03

L6             95 SEA SSS FUL L3 AND L1 NOT L2

=> => s l6
L7             10 L6

=> d l7 1-10 bib,ab,hitstr
```

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319718 CAPLUS
DN 138:338160
TI Preparation of diaminopyrimidines as inhibitors of β amyloid formation or its release
IN Himmelsbach, Frank; Fuchs, Klaus; Briem, Hans; Fechteler, Katja; Kostka, Markus; Dorner-Ciossek, Cornelia; Bornemann, Klaus; Klinder, Klaus
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032994	A2	20030424	WO 2002-EP11345	20021010
	WO 2003032994	A3	20030612		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003134838	A1	20030717	US 2002-272160	20021016
PRAI	US 2001-330128P	P	20011017		

OS MARPAT 138:338160
AB The title compds. [I; R1 = H, alkyl; R2 = (substituted) Ph; R3 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, alkenyl, alkynyl; R4 = H, alkyl; or NR3R4 = (substituted) 3-7 membered alkylenimino; R5 = NO2, amino, alkylamino, dialkylamino, etc.], were prepared Thus, 2-chloro-4-methylamino-5-nitropyrimidine and 3,4-dichloroaniline were heated in the presence of sulfolane for 45 min at 160° in an oil bath to give 90% 2-(3,4-dichlorophenylamino)-4-methylamino-5-nitropyrimidine. Several I inhibited formation of β amyloid with IC50 = 4-1100 μM.
IT **515826-60-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminopyrimidines useful for inhibiting β amyloid formation or its release)
RN 515826-60-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3,4-dichlorophenyl)-N4-methyl-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)


Cl
Cl
NH
N
N
MeNH
N

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:777930 CAPLUS
DN 137:294968
TI Preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer
IN Fischer, Peter Martin; Wang, Shudong; Wood, Gavin
PA Cyclacel Limited, UK
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079193	A1	20021010	WO 2002-GB1445	20020326
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1373253	A1	20040102	EP 2002-718319	20020326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008447	A	20040302	BR 2002-8447	20020326
	GB 2375534	A1	20021120	GB 2002-7229	20020327
	GB 2375534	B2	20030924		
PRAI	GB 2001-7901	A	20010329		
	WO 2002-GB1445	W	20020326		

OS MARPAT 137:294968
AB The title compds. [I; one of X1 and X2 = NR10 and the other of X1 and X2 = CR9; Z = NH, NHCO, NHSO2, etc.; R1-R3, R9, R10 = H, alkyl, aryl, etc.; R4-R8 = H, alkyl, halo, etc.; with the proviso], useful as inhibitors of cyclin-dependent kinases (CDKs) and hence useful in the treatment of proliferation disorders such as cancer, leukemia, psoriasis and the like, were prepared Thus, heating 3-dimethylamino-1-(2,4-dimethyl-1H-pyrrol-3-yl)propenone (preparation given) with 4-fluorophenyl guanidine nitrate in the presence of NaOH in 2-methoxyethanol at 100-120°C under N2 for 6 h afforded 62% II which showed IC50 of 1.0±0.7 μM against CDK2/cyclin E.
IT **467469-98-3P 467470-31-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer)
RN 467469-98-3 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-31-1 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-nitro-1H-pyrrol-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT **467469-99-4P 467470-00-4P 467470-01-5P**
467470-02-6P 467470-03-7P 467470-04-8P
467470-05-9P 467470-06-0P 467470-07-1P
467470-08-2P 467470-09-3P 467470-10-6P
467470-11-7P 467470-12-8P 467470-13-9P
467470-14-0P 467470-15-1P 467470-16-2P
467470-17-3P 467470-18-4P 467470-19-5P
467470-20-8P 467470-21-9P 467470-22-0P
467470-23-1P 467470-24-2P 467470-25-3P
467470-26-4P 467470-27-5P 467470-28-6P
467470-29-7P 467470-30-0P 467470-32-2P
467470-33-3P 467470-34-4P 467470-35-5P
467470-36-6P 467470-37-7P 467470-38-8P
467470-39-9P 467470-40-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer)

RN 467469-99-4 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 467470-00-4 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 467470-01-5 CAPLUS
CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-02-6 CAPLUS
CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-03-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-04-8 CAPLUS
CN Phenol, 4-[[4-(2,4-dimethyl-1H-pyrrol-3-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 467470-05-9 CAPLUS
CN Phenol, 3-[[4-(2,4-dimethyl-1H-pyrrol-3-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 467470-06-0 CAPLUS
CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-07-1 CAPLUS
CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)-(9CI) (CA INDEX NAME)



RN 467470-08-2 CAPLUS
CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-09-3 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 467470-10-6 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 467470-11-7 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-12-8 CAPLUS
CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-1H-pyrrol-3-yl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-13-9 CAPLUS
CN 2-Pyrimidinamine, N-(3-chloro-4-iodophenyl)-4-(2,4-dimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-14-0 CAPLUS
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-1H-pyrrol-3-yl)-N-(3-fluoro-4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 467470-15-1 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 3,5-dimethyl-4-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 467470-16-2 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-17-3 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-18-4 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 3,5-dimethyl-4-[2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 467470-19-5 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(4-iodophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-20-8 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-

3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-21-9 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 3,5-dimethyl-4-[2-[(4-methyl-3-nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 467470-22-0 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(3-iodo-4-methylphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-23-1 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(4-chloro-3-methylphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-24-2 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(3-hydroxy-4-methylphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-25-3 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(4-fluoro-3-methylphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-26-4 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[(3-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-27-5 CAPLUS
CN 1H-Pyrrole-2-carbonitrile, 4-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-28-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-29-7 CAPLUS
CN 2-Pyrimidinamine, 4-(3,5-dimethyl-1H-pyrrol-2-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-30-0 CAPLUS
CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(1,2,4-trimethyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 467470-32-2 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-nitro-1H-pyrrol-3-yl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 467470-33-3 CAPLUS
CN 2-Pyrimidinamine, 4-(5-amino-2,4-dimethyl-1H-pyrrol-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-34-4 CAPLUS
CN 2-Pyrimidinamine, 4-(5-bromo-2,4-dimethyl-1H-pyrrol-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-35-5 CAPLUS
CN 2-Pyrimidinamine, 4-(5-bromo-2,4-dimethyl-1H-pyrrol-3-yl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 467470-36-6 CAPLUS
CN 2-Pyrimidinamine, 4-(5-chloro-2,4-dimethyl-1H-pyrrol-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-37-7 CAPLUS
CN 2-Pyrimidinamine, 4-[5-[(diethylamino)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-38-8 CAPLUS
CN 2-Pyrimidinamine, 4-[5-[(dimethylamino)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-39-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2,4-dimethyl-5-(4-morpholinylmethyl)-1H-pyrrol-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 467470-40-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2,4-dimethyl-5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrrol-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:637673 CAPLUS
DN 137:185518
TI Pyrimidine derivatives as ERK2 inhibitors
IN Cao, Jingrong; Green, Jeremy; Hale, Michael; Maltais, Francois; Straub, Judy; Tang, Qing; Aronov, Alex
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064586	A2	20020822	WO 2002-US3791	20020208
	WO 2002064586	A3	20030206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092714	A1	20030515	US 2002-71699	20020208
	EP 1363906	A2	20031126	EP 2002-724922	20020208
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007114	A	20040225	BR 2002-7114	20020208
	NO 2003003491	A	20031008	NO 2003-3491	20030806
PRAI	US 2001-267818P	P	20010209		
	US 2001-328768P	P	20011012		
	WO 2002-US3791	W	20020208		

OS MARPAT 137:185518
AB Pyrimidnes I [Z1, Z2 = N, CH; X = 5-membered heteroarom. ring to which QR2 is attached in the 3-position relative to the pyrimidine ring attachment; T, Q = linker group; U = NR4, NR4CO, NR4CONR4, NR4CO2, O, CONR4, CO, CO2, O2C, NR4SO2, SO2NR4, NR4SO2NR4, SO2; m, n = 0, 1; R1 = CN, halogen, NR42, (un)substituted OH; R2 = (un)substituted alkyl, NH2; R3 = H, (un)substituted alkyl, CN; R4 = H, (un)substituted alkyl; NR42 = heterocyclic] were prepared for use as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, the pyrimidine II was obtained by cyclizing the 3-dimethylamino-2-methylacryloylpyrrole fragment with (S)-HOCH2CHPhNHC(:NH)NH2. II had ki <0.1 μM for inhibition of ERK2 in vitro.
IT **449731-22-0P 449731-23-1P 449731-30-0P**
449731-31-1P 449731-35-5P 449731-39-9P
449731-53-7P 449731-54-8P 449731-56-0P
449731-58-2P 449731-59-3P 449731-62-8P
449731-63-9P 449731-64-0P 449731-65-1P
449731-66-2P 449731-67-3P 449731-68-4P
449731-69-5P 449731-70-8P 449731-74-2P
449731-75-3P 449731-78-6P 449732-13-2P
449732-18-7P 449732-19-8P 449732-27-8P

449732-28-9P 449732-30-3P 449732-31-4P
449732-33-6P 449732-42-7P 449732-43-8P
449732-46-1P 449732-50-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as ERK2 inhibitors)

RN 449731-22-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-23-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]-N-[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-30-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)



RN 449731-31-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-35-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-39-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(2-aminoethyl)-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-53-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-54-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-56-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-58-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[4-(aminosulfonyl)phenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-59-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-62-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclopropyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-63-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-64-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-65-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-66-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 449731-67-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-68-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-69-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3,4-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-70-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-74-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-75-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-78-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-(methoxymethyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-13-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-18-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-19-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-27-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[3-(dimethylamino)phenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-28-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[(2-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-30-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-33-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-42-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-43-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-46-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-50-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **449731-17-3P 449731-38-8P 449731-45-7P**
449731-46-8P 449731-55-9P 449731-61-7P
449731-82-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as ERK2 inhibitors)

RN 449731-17-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449731-38-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-ethyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449731-45-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 449731-46-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methyl-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-55-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-61-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclohexyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-82-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(hydroxymethyl)-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:449662 CAPLUS
DN 137:33310
TI Preparation of anilinopyrimidines as IKK inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046171	A2	20020613	WO 2001-US46403	20011205
	WO 2002046171	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003203926	A1	20031030	US 2001-4642	20011204
	AU 2002020195	A5	20020618	AU 2002-20195	20011205
	EP 1349841	A2	20031008	EP 2001-999564	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-251816P	P	20001206		
	WO 2001-US46403	W	20011205		

OS MARPAT 137:33310
AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 1 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.
IT **434944-89-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrimidines as IKK inhibitors)
RN 434944-89-5 CAPLUS
CN Benzamide, 4-[[4-(1H-pyrrol-2-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:449661 CAPLUS
DN 137:33309
TI Preparation of anilinopyrimidines as JNK pathway inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003220330	A1	20031127	US 2001-4645	20011204
	AU 2002027214	A5	20020618	AU 2002-27214	20011205
	EP 1349840	A2	20031008	EP 2001-996103	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-251904P	P	20001206		
	WO 2001-US46402	W	20011205		

OS MARPAT 137:33309
AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 10 μM in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.
IT **434944-89-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrimidines as JNK pathway inhibitors)
RN 434944-89-5 CAPLUS
CN Benzamide, 4-[[4-(1H-pyrrol-2-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:457074 CAPLUS
DN 127:81461
TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719065	A1	19970529	WO 1996-GB2854	19961120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958935	A	19990928	US 1996-753041	19961119
	AU 9676314	A1	19970611	AU 1996-76314	19961120
	EP 862560	A1	19980909	EP 1996-939171	19961120
	EP 862560	B1	20030402		
	R: CH, DE, ES, FR, GB, IT, LI				
	ES 2195020	T3	20031201	ES 1996-939171	19961120
	US 6235746	B1	20010522	US 1999-249760	19990216
PRAI	GB 1995-23675	A	19951120		
	US 1996-753041	A3	19961119		
	WO 1996-GB2854	W	19961120		

OS MARPAT 127:81461
AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.
group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.
IT **191727-18-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)
RN 191727-18-1 CAPLUS
CN 2-Pyrimidinamine, 4-(1H-pyrrol-2-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI)

(CA INDEX NAME)



L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:495435 CAPLUS
DN 125:184908
TI Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)
AU Zimmermann, Juerg; Caravatti, Giorgio; Mett, Helmut; Meyer, Thomas; Mueller, Marcel; Lydon, Nicholas B.; Fabbro, Doriano
CS CIBA Pharmaceuticals Div., Oncology Virology Res. Dep., Ciba-Geigy Limited, Basel, CH-4002, Switz.
SO Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 371-376
CODEN: ARPMAS; ISSN: 0365-6233
PB VCH
DT Journal
LA English
AB Phenylamino-pyrimidines represent a novel class of inhibitors of protein kinase C with a high degree of selectivity vs. other serine/threonine and tyrosine kinases. Steady state kinetic anal. of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine , which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine preferentially inhibited PKC-α (IC50 = 0.79 μM) and not the other subtypes tested. The inhibition consts. of PKC-α and the antiproliferative effect on T24 human bladder carcinoma cells showed a qual. correlation, although with some exceptions.
IT **166306-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylamino-pyrimidine derivs. as a new class of potent and selective inhibitors of protein kinase C)
RN 166306-34-9 CAPLUS
CN 2-Pyrimidinamine, 4-(1H-pyrrol-2-yl)-N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:735375 CAPLUS
DN 123:169650
TI Preparation of N-(fluroralkoxyphenyl)-2-pyrimidineamines as drugs
IN Zimmermann, Juerg
PA Ciba-Geigy A.-G., Switz.
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509852	A1	19950413	WO 1994-EP3149	19940921
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5543520	A	19960806	US 1994-306333	19940915
	CA 2148477	AA	19950413	CA 1994-2148477	19940921
	AU 9476975	A1	19950501	AU 1994-76975	19940921
	AU 693804	B2	19980709		
	EP 672040	A1	19950920	EP 1994-927633	19940921
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08504834	T2	19960528	JP 1994-510576	19940921
PRAI	CH 1993-2966	A	19931001		
	CH 1994-2278	A	19940718		
	WO 1994-EP3149	W	19940921		

OS CASREACT 123:169650; MARPAT 123:169650
AB Title compds. [I; R1 = (N-oxido) 4-pyridyl, 3-indolyl, isoquinolyl, thienyl, pyrrolyl; R2 = fluoroalkoxy] were prepared as protein kinase C and tyrosine kinase inhibitors, etc. Thus, 3-(F2HCF2CO)C6H4NH2 was condensed with H2NCN and the guanidine product cyclocondensed with R1COCH:CHNMe2 (R1 = 4-pyridyl) to give I (R1 = 4-pyridyl, R2 = OCF2CHF2). I had IC50 of .apprx.0.1 to 9μmol/L against protein kinase C in vitro.
IT **166306-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(fluroralkoxyphenyl)-2-pyrimidineamines as drugs)
RN 166306-34-9 CAPLUS
CN 2-Pyrimidinamine, 4-(1H-pyrrol-2-yl)-N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:625910 CAPLUS
DN 119:225910
TI Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors
AU Paul, Rolf; Hallett, William A.; Hanifin, John W.; Reich, Marvin F.; Johnson, Bernard D.; Lenhard, Robert H.; Dusza, John P.; Kerwar, Suresh S.; Lin, Yang I.; et al.
CS Med. Res. Div., American Cyanamid Co., Pearl River, NY, 10965, USA
SO Journal of Medicinal Chemistry (1993), 36(19), 2716-25
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB A series of 4-aryl-2-(phenylamino)pyrimidines I (R = Ph, substituted Ph, R1 = 2-, 3-, 4-pyridyl, 2-, 3-thienyl, 2-, 3-furyl) were prepared as mediator release inhibitors, useful in treatment of asthma and other allergic disorders, and screened using human basophil. I were prepared by condensing heterocycles with R1COMe DMF di-Me acetal to form enaminones which were then cyclized with aryl guanidines RNHC(NH2):NH. After examining a large number of analogs, [(imidazolyl)phenylamino](pyrimidinyl)pyrimidine II was chosen for toxicol. evaluation.
IT **112722-32-4P 112722-50-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as agent for asthma treatment)
RN 112722-32-4 CAPLUS
CN 2-Pyrimidinamine, 4-(1-methyl-1H-pyrrol-2-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 112722-50-6 CAPLUS
CN 2-Pyrimidinamine, N-(3-methylphenyl)-4-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:112478 CAPLUS
DN 108:112478
TI Preparation of 4,5,6-substituted 2-pyrimidinamines as allergy inhibitors, antiasthmatics, and hypoglycemics
IN Torley, Lawrence Wayne; Johnson, Bernard B.; Dusza, John Paul
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 233461	A2	19870826	EP 1987-100277	19870112
	EP 233461	A3	19880525		
	EP 233461	B1	19960320		
	EP 233461	B2	20020529		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	US 4788195	A	19881129	US 1986-927572	19861106
	AT 135699	E	19960415	AT 1987-100277	19870112
	ES 2087056	T3	19960716	ES 1987-100277	19870112
	DK 8700151	A	19870714	DK 1987-151	19870113
	DK 171251	B1	19960812		
	FI 8700113	A	19870714	FI 1987-113	19870113
	FI 91150	B	19940215		
	FI 91150	C	19940525		
	AU 8767518	A1	19870716	AU 1987-67518	19870113
	AU 591223	B2	19891130		
	ZA 8700219	A	19870826	ZA 1987-219	19870113
	JP 62223177	A2	19871001	JP 1987-5867	19870113
	JP 07080857	B4	19950830		
	HU 43582	A2	19871130	HU 1987-100	19870113
	HU 198708	B	19891128		
	CA 1320201	A1	19930713	CA 1987-527173	19870113
	US 4876252	A	19891024	US 1988-194751	19880517
	AU 9050578	A1	19900726	AU 1990-50578	19900228
	AU 621461	B2	19920312		
PRAI	US 1986-817951	A	19860113		
	US 1986-927572	A3	19861106		

OS CASREACT 108:112478
AB The title compds. [I; R1 = H, C1-3 alkyl, EtO2CCO, Et2NCH2CH2; R2 = substituted Ph; R3 = Me2NC6H4, AcNMeC6H4, (un)substituted furanyl, thienyl, N-containing heteroaryl; R4, R5 = H, C1-3 alkyl] and their pharmacol. acceptable salts were prepared for treating asthma and allergic diseases, inflammation, and diabetes mellitus. A mixture of 7.04 g 3-(dimethylamino)-1-(3-pyridinyl)-2-propen-1-one and 18.72 g 3-F3CC6H4NHC(:NH)NH2.H2CO3 was refluxed 16 h in PrOH to give 5.55 g pyridinylpyrimidinamine II. II inhibited histamine release from immunol. stimulated human basophils with an IC50 of 0.7 μM. II also gave 58.1% inhibition of lipoxygenase activity in guinea pig neutrophils at 10 μg/mL.
IT **112676-16-1P 112696-42-1P 112722-31-3P**
112722-32-4P 112722-45-9P 112722-50-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)

RN 112676-16-1 CAPLUS
CN 2-Pyrimidinamine, N-(4-ethylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 112696-42-1 CAPLUS
CN 2-Pyrimidinamine, N-(4-ethylphenyl)-4-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 112722-31-3 CAPLUS
CN 2-Pyrimidinamine, N-(3-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 112722-32-4 CAPLUS
CN 2-Pyrimidinamine, 4-(1-methyl-1H-pyrrol-2-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 112722-45-9 CAPLUS
CN 2-Pyrimidinamine, N-phenyl-4-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 112722-50-6 CAPLUS
CN 2-Pyrimidinamine, N-(3-methylphenyl)-4-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 19:05:29 ON 20 APR 2004)

     FILE 'STNGUIDE' ENTERED AT 19:05:36 ON 20 APR 2004

     FILE 'HOME' ENTERED AT 19:05:39 ON 20 APR 2004

     FILE 'REGISTRY' ENTERED AT 19:05:47 ON 20 APR 2004
L1              SCREEN 1840
L2              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L3              STRUCTURE UPLOADED
L4              QUE L3 AND L1 NOT L2
L5            3 S L4 SSS SAM
L6           95 S L4 SSS FUL

     FILE 'CAPLUS' ENTERED AT 19:06:54 ON 20 APR 2004
L7           10 S L6

     FILE 'CAOLD' ENTERED AT 19:07:28 ON 20 APR 2004

=> s l6
L8            0 L6

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.42     204.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -6.93

STN INTERNATIONAL LOGOFF AT 19:07:42 ON 20 APR 2004
```